Mur għall-kontenut ewlieni

Żgurar tad-disponibbiltà tal-provvisti u tat-tagħmir

Availability of medical equipment

Disponibbiltà tat-tagħmir mediku

Mis-26 ta’ Mejju 2021, daħlu fis-seħħ ir-regoli l-ġodda dwar l-apparati mediċi (MDR), u b’hekk ġie stabbilit qafas regolatorju modern u aktar robust biex jiġu protetti s-saħħa pubblika u s-sikurezza tal-pazjenti. Ir-regoli l-ġodda bdew japplikaw wara posponiment ta’ sena minħabba l-isfidi bla preċedent tal-pandemija tal-coronavirus, u jindirizzaw il-ħtieġa għal disponibbiltà akbar ta’ apparati mediċi ta’ importanza vitali fl-UE kollha.

Disponibbiltà tal-mediċini

Il-Kummissjoni appellat biex il-pajjiżi tal-UE jiżguraw li matul il-pandemija tal-coronavirus l-Ewropej ikollhom aċċess għall-mediċini neċessarji u bi prezz tajjeb, filwaqt li tiġi ppreservata l-integrità tas-Suq Uniku. Dawn il-linji gwida jiżguraw il-provvista raġonevoli, it-trasport, l-allokazzjoni u l-użu ta’ mediċini vitali u jipprevjenu kwalunkwe skarsezza.

Identifikazzjoni tad-domanda u t-tlaqqigħ tal-provvisti ta’ tagħmir mediku

Il-Kummissjoni waqqfet “punt ċentrali ta’ koordinament għat-tagħmir mediku (COVID-19)” biex tidentifika l-provvisti disponibbli u tiffaċilita t-tlaqqigħ mad-domanda fil-pajjiżi tal-UE.

Dan serva bħala pjattaforma għad-djalogu u l-kondiviżjoni ta’ informazzjoni mar-rappreżentanti tal-Istati Membri dwar id-domanda u l-provvista ta’ tagħmir mediku fil-livell tal-UE u dwar mezzi biex jingħelbu n-nuqqasijiet u tinbena l-kapaċità.

Akkwist pubbliku ta’ tagħmir mediku u ta’ protezzjoni

Il-Ftehim ta’ Akkwist Konġunt volontarju għal kontromiżuri mediċi jippermetti x-xiri konġunt ta’ provvisti u tagħmir mediċi vitali. L-Akkwisti Konġunti jgħinu lill-Istati Membri jiġġieldu kontra l-pandemija tal-COVID-19 f’konformità mal-politiki tal-UE dwar l-ittestjar u t-tilqim.

Sa mill-bidu tal-2020, sa 36 pajjiż ipparteċipaw fi tnax-il proċedura ta’ akkwist konġunt, li rriżultaw f’aktar minn 200 kuntratt li ppermettew lill-pajjiżi jordnaw provvisti mediċi essenzjali u terapiji innovattivi għal kważi €13-il biljun. Meta twettaq akkwisti konġunti, il-Kummissjoni Ewropea għandha rwol ta’ koordinazzjoni, filwaqt li l-pajjiżi tal-UE jixtru l-oġġetti.

 

OĠĠETTI

DISPONIBBILTÀ

VOLUM

LIMITU MASSIMU TAL-BAĠIT

gloves icon

 

Ingwanti u coveralls

Avviż dwar għoti ta’ kuntratt 2020

April 2020-2021 (ingwanti)

Mejju 2020-2021 (coveralls)

Diversi miljuni

€97 miljun

eye respiratory protection icon

Protezzjoni għall-għajnejn u protezzjoni respiratorja

Avviż dwar għoti ta’ kuntratt 2020

Avviż dwar għoti ta’ kuntratt 2021

 April 2020-2021

20 miljun goggle

12-il miljun tarka tal-wiċċ

37 miljun maskra tat-tip FFP2

26 miljun maskra tat-tip FFP3

301 miljun maskra kirurġika

€1.4 biljun

ventilator icon

Ventilaturi

Avviż dwar għoti ta’ kuntratt 2020

 April 2020-2021

110,000 unità

€1.4 biljun

lab equipment

Tagħmir tal-laboratorju

Avviż dwar għoti ta’ kuntratt 2020

 Mejju 2020-2021

30 lott differenti

€192 miljun

medicines icon

Mediċini użati fl-unitajiet tal-kura intensiva

Ottubru 2020 - Settembru 2022*

103 miljun kunjett ta’ 19-il mediċina (analġeżiċi, antibijotiċi, rilassaturi tal-muskoli, anestetiċi, risuxxitazzjoni, oħrajn)

NB. Inkluż id-deksametażon taħt il-lott 1

(L-Aġenzija Ewropea għall-Mediċini tapprova l-użu tad-deksametażon f’pazjenti bil-COVID-19 fuq l-ossiġenu jew il-ventilazzjoni mekkanika)

€543 miljun

veklury icon

Remdesivir (Veklury)

Avviż dwar għoti ta’ kuntratt 2020

 Ottubru 2020 - April 2022*

Aktar minn 500,000 kors ta’ trattament

(Aġenzija Ewropea għall-Mediċini - kundizzjonijiet tal-użu)

€3.4 biljun

vaccines graphic

Tagħmir mediku għat-tilqim

Avviż dwar għoti ta’ kuntratt 2021

Diċembru 2020 - Marzu 2022* 1.2 biljun siringa
588 miljun labra
760 miljun par ingwanti
307 miljun fardal
1.18 miljun kontenitur għat-trasport tal-vaċċini
3.38 miljun kontenitur tal-iskart
98 miljun diżinfettant
5.5 miljun anestetiku għall-konsum
€2.27 biljun
rapid test graphic

Testijiet tal-antiġeni rapidi

Avviż dwar għoti ta’ kuntratt 2021

Frar 2021 - 2022

557 miljun test

1,733 apparat tal-qari

€2.67 biljun
antibody graphic

Antikorpi monoklonali

 

April 2021 - tmiem l-2021***

220,000 trattament ta’ VIR-7831 (sotrovimab)

220,000 trattament tat-taħlita ta’ bamlanivimab u etesevimab

55,000 trattament ta’ Regn-COV2 (taħlita ta’ casirivimab u imdevimab)

€937 miljun

* Skont id-data tal-iffirmar tal-kuntratt.

** Tiġdid ta’ żewġ kuntratti. 

*** B'estensjoni possibbli tal-kuntratt. 

Gwida dwar l-użu tal-qafas tal-akkwist pubbliku

Riżerva u distribuzzjoni tal-provvisti u tat-tagħmir

Ir-riżerva tar-RescEU hija riżerva Ewropea komuni ta’ apparat mediku bħal:

  • ventilaturi
  • tagħmir protettiv personali
  • maskri li jistgħu jerġgħu jintużaw
  • vaċċini u aġenti terapewtiċi
  • provvisti għal-laboratorji

Il-Kummissjoni tiffinanzja 100% tal-ispejjeż tal-kumulazzjoni tar-riżerva u se timmaniġġja d-distribuzzjoni tat-tagħmir biex tiżgura li dan imur fejn l-aktar hemm bżonnu.

Żieda tal-kapaċitajiet Ewropej ta’ produzzjoni

Standards armonizzati riveduti se jippermettu lill-manifatturi jagħmlu apparat ta’ kwalità għolja biex jipproteġu lill-pazjenti, lill-professjonisti tal-kura tas-saħħa u liċ-ċittadini b’mod ġenerali. L-istandards riveduti jirrelataw ma’ provvisti kritiċi bħal

  • maskri mediċi
  • ħwejjeġ protettivi
  • lożor kirurġiċi
  • aġent ta’ diżinfettant u sterilizzazzjoni
  • protezzjoni tal-għajnejn personali
  • ingwanti mediċi
  • apparati respiratorji protettivi

Il-Kummissjoni għamlet gwida disponibbli fi 3 oqsma biex tgħin lill-manifatturi biex iżidu l-produzzjoni ta’ tagħmir u materjal mediku essenzjali, l-aktar

Gwida dwar l-apparati mediċi

Tneħħija temporanja tad-dazji doganali u tal-VAT fuq l-importazzjonijiet

Il-Kummissjoni approvat it-talbiet mill-pajjiżi tal-UE kollha u mir-Renju Unit biex jitneħħew b’mod temporanju d-dazji doganali u l-VAT fuq l-importazzjoni tal-apparati mediċi u tat-tagħmir protettiv minn pajjiżi terzi. Ir-rinunzja temporanja reġgħet ġiet estiża sal-31 ta’ Diċembru 2021.

Il-Kummissjoni ppubblikat ukoll gwida speċjalizzata biex tiffaċilita x-xogħol tal-awtoritajiet doganali tal-Istati Membri u ta’ partijiet ikkonċernati rilevanti oħra, meta jittrattaw il-proċeduri doganali, pereżempju, il-minimizzazzjoni tal-formalitajiet tal-importazzjoni tal-organi umani u tal-mudullun li jkunu destinati għat-trapjanti fl-UE jew ta’ diversi faċilitajiet ta’ pagament tad-dejn doganali jew tal-provi tal-oriġini preferenzjali tal-oġġetti.

Il-Kummissjoni pproponiet ukoll li l-isptarijiet u l-prattikanti mediċi m’għandhomx iħallsu l-VAT fuq il-vaċċini u fuq il-kits tal-ittestjar. Wara l-approvazzjoni mill-Istati Membri, dawn il-miżuri temporanji ta’ ħelsien mill-VAT se japplikaw sal-31 ta’ Diċembru 2022.

Il-Kummissjoni tipproponi wkoll eżenzjoni mill-VAT tal-oġġetti u s-servizzi vitali distribwiti mill-UE fi żminijiet ta’ kriżi. L-inizjattiva se timmassimizza l-effiċjenza tal-fondi tal-UE użati fl-interess pubbliku meta tirreaġixxi għall-kriżijiet.

Il-Fond Ewropew ta’ Solidarjetà se jindirizza l-pandemija tal-coronavirus

Fil-11 ta’ Marzu 2021, il-Kummissjoni Ewropea ressqet pakkett ta’ kważi €530 miljun f’appoġġ finanzjarju addizzjonali taħt il-Fond ta’ Solidarjetà tal-UE. Dan se jikkontribwixxi għall-isforzi mwettqa minn 17-il Stat Membru u 3 pajjiżi ta’ adeżjoni (l-Awstrija, il-Belġju, iċ-Ċekja, l-Estonja, Franza, il-Ġermanja, il-Greċja, l-Irlanda, l-Italja, il-Kroazja, il-Latvja, il-Litwanja, il-Lussemburgu, il-Portugall, ir-Rumanija, Spanja, l-Ungerija u l-Albanija, il-Montenegro u s-Serbja) biex tiġi ssalvagwardjata s-saħħa pubblika fil-ġlieda kontra l-coronavirus.

Il-finanzjament se jappoġġja parti min-nefqa pubblika tagħhom fuq tagħmir protettiv mediku u personali, appoġġ ta’ emerġenza għall-popolazzjoni, u miżuri għall-prevenzjoni, il-monitoraġġ u l-kontroll tat-tixrid tal-marda. Ladarba tiġi approvata mill-Parlament Ewropew u mill-Kunsill, l-għajnuna finanzjarja mbagħad se tiġi żborżata lill-pajjiżi applikanti.

Availability of medicines

The Commission has called on EU countries to ensure that Europeans have access to necessary and affordable medicines during the coronavirus outbreak while preserving the integrity of the Single Market. These guidelines ensure the rational supply, transport, allocation and use of vital medicines and prevent any shortages.

Identifying demands and matching supplies of medical equipment

The Commission set up a ‘clearing house for medical equipment (COVID-19)’ to identify available supplies and facilitate the matching with demand in EU countries.

It served as a platform for dialogue and sharing of information with Member States’ representatives on the demand and supply of medical equipment at EU level and on means to overcome shortages and build capacity.

Public procurement of medical and protective equipment

The voluntary Joint Procurement Agreement for medical countermeasures enables the joint purchase of vital medical supplies and equipment. Joint Procurements help Member States to fight the COVID-19 pandemic in line with the EU policies on testing and vaccination.

Since early 2020, up to 36 countries, participated in twelve joint procurement procedures, which resulted in over 200 contracts allowing countries to order essential medical supplies and innovative therapeutics for nearly €13 billion. When conducting joint procurements, the European Commission has a coordinating role, while the EU countries purchase the items.

 

ITEMS

AVAILABILITY

VOLUME

BUDGET CEILING

gloves icon

 

Gloves and coveralls

Contract award notice 2020

April 2020-2021 (gloves)

May 2020-2021 (coveralls)

Several million

€97 million

eye respiratory protection icon

Eye and respiratory protection

Contract award notice 2020

Contract award notice 2021

 April 2020-2021

20 million goggles

12 million face shields

37 million FFP2 masks

26 million FFP3 masks

301 million surgical masks

€1.4 billion

ventilator icon

Ventilators

Contract award notice 2020

 April 2020-2021

110,000 units

€1.4 billion

lab equipment

Laboratory equipment

Contract award notice 2020

 May 2020-2021

30 different lots

€192 million

medicines icon

Medicines used in intensive care units

October 2020 - September 2022*

103 million vials of 19 medicines (analgesics, antibiotics muscle relaxers, anaesthetics, resuscitation, other)

NB. Includes dexamethasone under lot 1

(European Medicines Agency endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation)

€543 million

veklury icon

Remdesivir (Veklury)

Contract award notice 2020

 October 2020 - April 2022**

Over 500,000 treatment courses

(European Medicines Agency - conditions of use)

€3.4 billion

vaccines graphic

Medical equipment for vaccination

Contract award notice 2021

December 2020 - March 2022* 1.2 billion syringes
588 million needles
760 million pairs of gloves
307 million aprons
1.18 million vaccine carriers
3.38 million waste containers
98 million disinfectants
5.5 million anaesthetic consumables
€2.27 billion
rapid test graphic

Rapid antigen tests

Contract award notice 2021 

February 2021 - 2022

557 million tests

1,733 reading devices

€2.67 billion
antibody graphic

Monoclonal antibodies

 

April 2021 - end 2021***

220,000 treatments of VIR-7831 (sotrovimab)

220,000 treatments of bamlanivimab and etesevimab combination

55,000 treatments of Regn-COV2 (combination of casirivimab and imdevimab)

€937 million

* Depending on the contract signature date.

** Two contract renewals. 

*** With a possible contract extension. 

Guidance on using the public procurement framework

Stockpiling and distributing supplies and equipment

The rescEU stockpile is a common European reserve of medical equipment such as:

  • ventilators
  • personal protective equipment
  • reusable masks
  • vaccines and therapeutics
  • laboratory supplies

The Commission finances 100% of the costs of the stockpiling and will manage the distribution of the equipment to ensure it goes where it is needed most.

Increasing European production capacities

Revised harmonised standards will allow manufacturers to make high quality devices to protect patients, healthcare professionals and citizens in general. The revised standards relate to critical supplies such as

  • medical facemasks
  • protective clothing
  • surgical drapes
  • disinfectant and sterilization agent
  • personal eye protection
  • medical gloves
  • respiratory protective devices

The Commission has made guidance available in 3 areas to assist manufacturers in increasing the output of essential medical equipment and material, namely

Guidance on medical devices

Temporarily lifting customs duties and VAT on imports

The Commission approved requests from all EU countries and the UK to temporarily waive customs duties and VAT on the import of medical devices, and protective equipment, from third countries. The temporary waiver has been extended again until 31 December 2021.

The Commission also published specialised guidance to ease the work of Member State customs authorities, and other relevant stakeholders, when dealing with customs procedures, e.g. minimising formalities on the import of human organs and bone marrow destined for transplant in the EU or various payment facilities for handling customs debt or proving preferential origin of goods.

The Commission also proposed that hospitals and medical practitioners should not have to pay VAT on vaccines and testing kits. Following the green light by Member States, these temporary VAT relief measures will apply until 31 December 2022.

The Commission also proposes to exempt vital goods and services distributed by the EU from VAT in times of crisis. The initiative will maximise the efficiency of EU funds used in the public interest when responding to crises.

European Solidarity Fund to address the coronavirus pandemic

On 11 March 2021, the European Commission put forward a package of almost €530 million in additional financial support under the EU Solidarity Fund. It will contribute to the efforts deployed by 17 Member States and 3 accession countries (Austria, Belgium, Croatia, Czechia, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Portugal, Romania, Spain and Albania, Montenegro and Serbia) to safeguard public health in fighting the coronavirus.

The funding will support part of their public expenditure on medical and personal protective equipment, emergency support to the population, and measures to prevent, monitor and control of the spread of the disease. Once approved by the European Parliament and the Council, the financial aid will then be disbursed to the applicant countries.